Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more
Humacyte Inc (HUMA) - Total Assets
Latest total assets as of September 2025: $91.51 Million USD
Based on the latest financial reports, Humacyte Inc (HUMA) holds total assets worth $91.51 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Humacyte Inc - Total Assets Trend (2019–2024)
This chart illustrates how Humacyte Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Humacyte Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Humacyte Inc's total assets of $91.51 Million consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Humacyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humacyte Inc's current assets represent 34.7% of total assets in 2024, a decrease from 56.3% in 2019.
- Cash Position: Cash and equivalents constituted 32.6% of total assets in 2024, down from 55.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Humacyte Inc Competitors by Total Assets
Key competitors of Humacyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Humacyte Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Humacyte Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Humacyte Inc is currently not profitable relative to its asset base.
Humacyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.62 | 1.10 | 3.69 |
| Quick Ratio | 0.90 | 1.10 | -5.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.77 Million | $ 2.06 Million | $ 30.22 Million |
Humacyte Inc - Advanced Valuation Insights
This section examines the relationship between Humacyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 57.77 |
| Latest Market Cap to Assets Ratio | 1.32 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | $137.87 Million |
| Market Capitalization | $182.16 Million USD |
Valuation Analysis
Above Book Valuation: The market values Humacyte Inc's assets above their book value (1.32 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Humacyte Inc's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Humacyte Inc (2019–2024)
The table below shows the annual total assets of Humacyte Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $137.87 Million | +7.53% |
| 2023-12-31 | $128.22 Million | -37.24% |
| 2022-12-31 | $204.30 Million | -28.70% |
| 2021-12-31 | $286.53 Million | +168.57% |
| 2020-12-31 | $106.69 Million | -36.76% |
| 2019-12-31 | $168.69 Million | -- |